CE/CME Statement

Intended Audience

This activity was developed for pulmonologists and other clinicians involved in the diagnosis and management of idiopathic pulmonary fibrosis

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Discuss diagnostic, scientific, and therapeutic advances in the field of idiopathic pulmonary fibrosis (IPF)
  • Identify practice changes that might be right for your clinic or office based on recent diagnostic, scientific, and therapeutic advances in IPF


Harold R. Collard, MD (faculty)
Associate Professor of Medicine
Director, Interstitial Lung Disease Program 
University of California, San Francisco
San Francisco, California

Hassan Bencheqroun, MD, FCCP (discussant)
Pacific Pulmonary Medical Group
Assistant Clinical Professor, Interventional Pulmonary and Clinical Care
University of California, Riverside School of Medicine
Riverside, California

Ahmed S. El-Bershawi, MD (discussant)
Medical Director and CEO
Pacific Pulmonary Medical Group
Medical Director, ICU & Respiratory Departments
Riverside Community and Parkview Community Hospitals
Riverside, California

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Harold R. Collard, MD

Consultant : AstraZeneca, ImmuneWorks, Bayer, Biogen, Boehringer Ingelheim, FibroGen, Genentech, Genoa, Gilead, Mesoblast, Moerae Matrix, PatientsLikeMe, Pfizer, Promedior, Prometix, Pulmatrix


The following faculty have no relevant financial relationships to disclose:

Hassan Bencheqroun, MD, FCCP
Ahmed S. El-Bershawi, MD

The faculty for this activity have disclosed that there will be discussion about the use of products for non-FDA approved indications.

Additional content planners

The following have no significant relationship to disclose.

Josh Paul (medical writer)

Annenberg Center for Health Sciences

John Bayliss, VP, Business Development, spouse is an employee of Amgen, Inc; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Supported by an educational grant from Genentech.

This activity is an online enduring material. Successful completion is achieved by reading and viewing the material, reflecting on its implications in your practice, and completing the assessment component.

The estimated time to complete the activity is 1.5 hours.

Our Policy on Privacy

Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us, or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at http://www.annenberg.net/privacy-terms.shtml

Contact Information

39000 Bob Hope Drive 
Dinah Shore Building
Rancho Mirage, CA 92270
Phone    760-773-4500
Fax    760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday